Dry Mouth (Xerostomia) — Assessment & Management

Safety

Red Flags — Malignancy, Systemic Disease & Severe Sequelae

Done

Dry mouth + dry eyes + bilateral parotid swelling + positive anti-Ro/La antibodies + arthralgia in a middle-aged woman Primary Sjögren disease — systemic autoimmune exocrinopathy. → Rheumatology/oral medicine referral. Primary care: ANA + anti-Ro/La and baseline bloods; lip biopsy, Schirmer and salivary-flow testing are specialist decisions — no single test is diagnostic. Lymphoma risk is increased (stay alert to warning features).

Dry mouth + unilateral firm painless parotid mass + facial nerve weakness + cervical lymphadenopathy Parotid gland malignancy (mucoepidermoid carcinoma, acinic cell carcinoma). → Persistent, unexplained or suspicious salivary gland swelling: refer via the local head and neck/ENT pathway — urgently if there is a firm mass, facial weakness, fixation or neck nodes. (Salivary gland swelling is not a NICE NG12 criterion; an unexplained neck lump is.) Facial nerve weakness, fixation, rapid enlargement, skin involvement or cervical lymphadenopathy increase concern for malignancy. Do not arrange CT/MRI or biopsy routinely in primary care before referral unless this is explicitly part of the local pathway.

Dry mouth + recurrent dental caries despite good oral hygiene + multiple tooth loss + severe xerostomia not responding to measures Severe xerostomia with significant oral complications. → Specialist dental referral (community dental service or hospital dentistry). The dentist may prescribe high-fluoride toothpaste or apply fluoride varnish. Neutral-pH saliva substitutes.

Dry mouth + polydipsia + polyuria + weight loss + elevated blood glucose Undiagnosed or poorly controlled diabetes mellitus — dehydration + osmotic diuresis. → Capillary glucose today, with blood ketones if glucose is raised. Raised ketones, vomiting or unwell → same-day hospital assessment (999 if drowsy or breathing fast). Suspected type 1 diabetes → same-day diabetes-team assessment (child or young person: same-day paediatric diabetes team, NICE NG18). Otherwise HbA1c to confirm, then the diabetes pathway.

Dry mouth + bilateral parotid enlargement + bilateral lacrimal gland enlargement + elevated ACE + hilar lymphadenopathy on CXR Sarcoidosis with glandular involvement (Heerfordt syndrome — uveoparotid fever). → If sarcoidosis is clinically suspected: CXR ± serum ACE (non-specific) and specialist referral (respiratory/rheumatology) — diagnosis generally requires specialist imaging and tissue assessment. Not routine for every bilateral parotid swelling.

Dry mouth + mucositis + mouth ulcers + dry eyes + skin rash + recent allogeneic stem cell transplant Chronic graft-versus-host disease (cGVHD) — salivary gland involvement causing sicca syndrome. → Haematology/BMT team urgently; any systemic immunosuppression is specialist-led.

Sjögren disease is often diagnosed late, largely because xerostomia and xerophthalmia are attributed to medications, ageing, or anxiety without serological investigation. It is much commoner in women, with peak onset in middle age. The most important primary care principle: any patient with both dry mouth AND dry eyes (the sicca complex), particularly a middle-aged woman, should have ANA + anti-Ro (SSA) + anti-La (SSB) requested. Anti-Ro positivity strongly supports Sjögren disease but does not by itself confirm it — false positives and other connective-tissue diseases occur. Extraglandular consequences include peripheral neuropathy, interstitial lung disease, renal tubular acidosis and an increased risk of non-Hodgkin B-cell lymphoma (predominantly MALT-type, often in the parotid). The lifetime risk is often quoted at approximately 5–10%, much higher in selected subgroups — do not present this as an individual risk estimate.

Diagnose

Causes of Xerostomia — Classification

Done

Medication-induced (most common cause in primary care)

Medications that cause xerostomia by reducing salivary flow via anticholinergic or sympathomimetic mechanisms. Most culpable: antimuscarinics (oxybutynin, solifenacin, tolterodine — OAB treatment); tricyclic antidepressants (amitriptyline, dosulepin, imipramine); antipsychotics (clozapine, olanzapine, quetiapine); antihistamines (chlorphenamine, hydroxyzine — sedating first-generation); antihypertensives (diuretics — dehydration; ACE inhibitors; alpha-blockers); SSRIs/SNRIs (paroxetine most anticholinergic; venlafaxine); opioids (all opioids reduce salivary flow); diuretics (furosemide, bendroflumethiazide — volume depletion). Cumulative: polypharmacy with several anticholinergic medicines is a particularly potent cause — calculate Anticholinergic Cognitive Burden (ACB) score.

Systemic and autoimmune causes

Primary Sjogren syndrome: autoimmune destruction of exocrine glands (salivary + lacrimal). Secondary Sjogren: associated with RA, SLE, or systemic sclerosis. Diabetes mellitus (poorly controlled — osmotic dehydration, microangiopathy of salivary gland vessels). Hypothyroidism (reduced basal metabolic rate + reduced secretory function). Sarcoidosis (granulomatous infiltration of salivary glands). HIV infection (HIV-associated salivary gland disease — parotid enlargement + xerostomia). Hepatitis C. Amyloidosis (infiltration). IgG4-related disease. Graft-versus-host disease.

Local and iatrogenic causes

Head and neck radiotherapy: can cause permanent acinar cell destruction — the most severe form of iatrogenic xerostomia. Surgical: bilateral parotidectomy, submandibular gland excision. Dehydration (systemic — inadequate intake, fever, diarrhoea/vomiting). Mouth breathing (chronic — bypasses nasal humidification, dries oral mucosa). Anxiety and stress (sympathetic activation reduces parasympathetic salivary drive temporarily). Ageing (modest reduction in salivary flow in healthy ageing — exacerbated by medications).

The anticholinergic burden scoring in polypharmacy is an essential primary care tool for identifying medication-induced xerostomia — the Anticholinergic Cognitive Burden (ACB) scale assigns each anticholinergic medication a score of 1 (mild), 2 (moderate), or 3 (severe). A total ACB score ≥3 is associated with significant anticholinergic effects including xerostomia, constipation, urinary retention, confusion, and impaired cognitive function. Common high-scoring medications: amitriptyline (3), oxybutynin (3), chlorphenamine (3), tolterodine (3), olanzapine (3), paroxetine (3), clozapine (3). Medicines optimisation for dry mouth should include a systematic ACB calculation for every patient on three or more of these drug classes — if ACB total ≥3, consider: switching amitriptyline to nortriptyline (lower anticholinergic burden), switching to a less anticholinergic antihistamine (loratadine = 0), switching oxybutynin to mirabegron (beta-3 agonist — no anticholinergic effect).

Diagnose

Assessment — History, Examination & Investigations

Done

History

First confirm true xerostomia versus thirst or altered oral sensation. Symptom characterisation: constant or intermittent dryness, severity (Likert 0-10 scale), impact on eating/swallowing (particularly dry or crumbly foods — crackers, bread), speaking, tasting, wearing dentures (suction reduced), sleeping (mouth dryness at night). Associated sicca symptoms: dry eyes (foreign body sensation, burning, photophobia — ask explicitly), dry nose, dry skin, dry vagina. Dental: caries (accelerated in xerostomia — saliva neutralises acid, remineralises enamel), oral candidiasis, difficulty wearing dentures. Systemic: fatigue, joint pain, skin rash, Raynaud's, neuropathy, renal and respiratory symptoms (Sjögren associations). Medications: full list including OTC, recreational, herbal (kava, ephedra — some cause dry mouth). Radiotherapy history (head/neck). Duration: acute (medication change, illness) vs chronic. Thirst and urine output (diabetes). Parotid swelling.

Examination

Oral mucosa: degree of dryness (clinical rating: grade 1 = slightly dry, grade 2 = moderately dry with absent saliva pooling, grade 3 = severely dry with cracked lips and parched mucosa). Tongue: dry, fissured, depapillated, reddened (candidal glossitis, vitamin deficiency). Teeth: generalised cervical caries (caries at the neck of teeth — characteristic pattern of xerostomia-related decay). Angular cheilitis. Candidiasis (white plaques or erythematous mucosa under dentures). Parotid glands: bilaterally enlarged (Sjogren, sarcoidosis, HIV, alcoholism), unilateral firm mass (malignancy — urgent ENT referral, local pathway). Cervical lymph nodes. Submandibular duct orifice: express saliva by milking gland from behind forward — assess quantity, clarity, and character.

Investigations

All persistent unexplained xerostomia: medication review; oral and dental examination; glucose/HbA1c and TFTs if clinically indicated; FBC, U&Es, LFTs if systemic illness or autoimmune disease is suspected. If sicca syndrome is clinically suspected: ANA · anti-Ro/SSA ± anti-La/SSB · ESR/CRP · immunoglobulins + serum protein electrophoresis · FBC + renal function (U&Es/eGFR), LFTs · urinalysis + ACR if renal/systemic disease is possible. Targeted only: HIV/HCV testing according to risk and presentation; ACE and chest imaging if sarcoidosis is clinically suspected; serum IgG4 only if IgG4-related disease is a genuine differential; coeliac serology if compatible symptoms or associated autoimmune disease. Specialist only: lip biopsy, Schirmer testing, ocular staining and salivary-flow testing — decided by rheumatology/oral medicine.

The unstimulated whole salivary flow rate (UWSFR) is an objective measure of salivary output that supplements the clinical diagnosis of xerostomia — patients collect all saliva for 15 minutes by allowing it to drip from their lips into a pre-weighed container (unstimulated, no chewing or swallowing), and the result is expressed in mL per minute. In the 2016 ACR/EULAR criteria, an unstimulated whole salivary-flow rate ≤0.1 mL/minute scores 1 point. This test is performed in specialist oral medicine or rheumatology clinics — GPs will not routinely perform it, but should be aware that a specialist may report it when assessing Sjogren syndrome or radiation-induced xerostomia. The subjective complaint of dry mouth does not always correlate with objective flow rates — some patients with measurable salivary flow still report significant dryness (possibly due to altered saliva composition rather than just reduced quantity).

Diagnose

Sjogren Syndrome Diagnosis & Parotid Gland Disease

Done

Sjogren syndrome — ACR/EULAR 2016 classification criteria

Use the 2016 ACR/EULAR criteria as a diagnostic framework in patients with clinically significant sicca symptoms. Diagnosis should be made by rheumatology/oral medicine using the clinical picture, serology and objective glandular/ocular testing. No single test is diagnostic. Score ≥4 = meets classification criteria (classification criteria, interpreted clinically — not a standalone diagnostic test). Labial salivary-gland biopsy with focal lymphocytic sialadenitis (focus score ≥1 focus/4 mm²) = 3 points. Anti-Ro/SSA antibody positive = 3 points. Ocular staining score ≥5 (or van Bijsterveld score ≥4) = 1 point. Schirmer's test ≤5 mm/5 min = 1 point. Unstimulated whole salivary flow ≤0.1 mL/min = 1 point. (Ocular staining with lissamine green or fluorescein is counted once, in the ocular staining item above.) Anti-La/SSB, ANA and rheumatoid factor are clinically relevant but are not independent scoring items. Exclusion criteria: previous head-and-neck radiotherapy, active hepatitis C infection, HIV/AIDS, sarcoidosis, amyloidosis, graft-versus-host disease, IgG4-related disease.

Parotid gland differential diagnosis

Bilateral painless enlargement: Sjogren syndrome (most important to exclude), sarcoidosis (firm, non-tender), HIV sialadenopathy (diffuse parotid enlargement + cystic lesions on USS — benign lymphoepithelial cysts), IgG4-related disease (IgG4-RD — bilateral parotid + submandibular enlargement + elevated serum IgG4), recurrent parotitis of childhood (recurrent painful swelling, resolves by adulthood), bulimia nervosa (parotid hypertrophy from repeated vomiting — amylase elevated), alcohol-related sialadenosis (bilateral painless enlargement without pain). Unilateral painful swelling: parotitis (acute bacterial — S. aureus — or viral — mumps), parotid duct stone (sialolithiasis — pain worse during eating, swelling that reduces after eating). Unilateral painless hard mass: parotid neoplasm (pleomorphic adenoma = most common benign; Warthin tumour; malignant = mucoepidermoid carcinoma) → urgent referral via the local head and neck/ENT pathway (firm mass). Bilateral diffuse enlargement in Sjögren disease may reflect chronic sialadenitis rather than malignancy — no routine biopsy for stable bilateral enlargement; specialist imaging and ultrasound-guided biopsy when there is a focal lesion, asymmetry, rapid enlargement, lymphadenopathy or other lymphoma concern.

IgG4-related disease (IgG4-RD) — distinguishing from Sjogren

IgG4-RD: systemic fibro-inflammatory disease characterised by IgG4+ plasma cell infiltration with storiform fibrosis. Mimics Sjogren: bilateral painless submandibular + parotid + lacrimal gland swelling (Mikulicz disease). Serum IgG4 can be normal in IgG4-RD and elevated in other conditions; diagnosis generally requires specialist clinical assessment, imaging and often tissue histology. Consider IgG4-related disease where there is persistent bilateral salivary/lacrimal enlargement, pancreatic or renal disease, lymphadenopathy or other compatible organ involvement. Refer to rheumatology/ENT/oral medicine; do not start corticosteroids in primary care solely on the basis of an elevated IgG4.

IgG4-related disease is an increasingly recognised cause of bilateral salivary and lacrimal gland enlargement (historically termed Mikulicz disease) that is clinically indistinguishable from Sjogren syndrome on examination — both present with bilateral parotid, submandibular, and lacrimal gland swelling with associated sicca symptoms. Serum IgG4 alone does not confirm or exclude IgG4-RD — it can be normal in the disease and raised in other conditions; diagnosis needs specialist clinical assessment, imaging and often histology (storiform fibrosis, obliterative phlebitis, IgG4+ plasma cells). Treatment, including corticosteroids, is specialist-led and should not be started in primary care on the basis of an elevated IgG4. Request serum IgG4 only if IgG4-related disease is a genuine differential.

Refer

Referral Pathways

Done

Urgent ENT referral (local pathway)

Persistent, unexplained or suspicious salivary gland swelling (local head and neck/ENT pathway; urgent if firm mass, facial weakness, fixation or neck nodes) · Unilateral hard painless parotid mass (parotid neoplasm) · Parotid mass with facial nerve weakness or cervical nodes · Rapidly enlarging or asymmetric gland · Severe dental complications → specialist dental/oral medicine (community or hospital dentistry) · cGVHD symptoms after allogeneic transplant → transplant team

Rheumatology / oral medicine

Suspected Sjögren disease (sicca symptoms ± anti-Ro/La positivity — positivity supports but does not by itself confirm the diagnosis) → specialist assessment and diagnosis. Sjögren disease with B symptoms, cytopenias, lymphadenopathy, purpura or new systemic disease (peripheral neuropathy, renal involvement) → urgent. IgG4-RD suspected → rheumatology/ENT/oral medicine; do not start corticosteroids in primary care.

Oral medicine / hospital dentistry

Severe xerostomia causing dental complications (rampant caries, recurrent oral candidiasis, denture problems) · Post-radiotherapy xerostomia management (specialised moistening + fluoride protocols) · Sjogren-related oral complications

Endocrinology / diabetes service

Diabetes confirmed (HbA1c ≥48 mmol/mol) as cause of dry mouth → diabetes management pathway

GP management

Medication-induced xerostomia: medication review — reduce or switch causative drugs where clinically feasible. Symptomatic relief: offer a saliva substitute or stimulant according to patient preference, availability and local formulary — neutral-pH (and, where available, fluoride-containing) for people with natural teeth; check ACBS criteria before prescribing. Regular sips of water, sugar-free gum or lozenges where salivary tissue remains, humidification for selected patients. Dental prevention advice and dental review according to caries risk (high-fluoride products are dental-led). Consider pilocarpine only after contraindication and residual-function assessment, per current SPC and local formulary.

Lymphoma vigilance in Sjögren disease is risk- and symptom-guided — there is no universal annual lymphoma blood-screening schedule. The risk of B-cell lymphoma (predominantly MALT-type arising in salivary glands) is increased, so be alert to: persistent or asymmetric parotid enlargement, rapidly worsening gland swelling, new lymphadenopathy or splenomegaly, unexplained weight loss, fever or night sweats, palpable purpura, cryoglobulinaemia, low complement (especially C4), monoclonal gammopathy, persistent cytopenias, and new peripheral neuropathy or renal disease. Any of these requires prompt specialist assessment (BSR 2024).

Treat

Saliva Substitutes, Sialogogues & Medication Review

Done

Artificial saliva and topical measures

Offer a saliva substitute or stimulant according to patient preference, availability and local formulary. For people with natural teeth, prefer a neutral-pH and, where available, fluoride-containing product. Check ACBS criteria before prescribing. No single product is clearly superior (NHS SPS); availability changes, some products are OTC only, some are ACBS-approved only for radiotherapy-related xerostomia or sicca syndrome, some are acidic (may increase erosion/caries risk) and some contain animal-derived ingredients. Sprays suit daytime use; gels suit nocturnal dryness. Apply before meals (to aid chewing/swallowing), before bed (nocturnal dryness), and as required. Water: encourage regular small sips (unless fluid restriction applies) — swishing rather than swallowing is more efficient at moistening mucosa.

Stimulation of residual salivary function

Sugar-free chewing gum: stimulates reflex salivary flow via mechanoreceptors — effective if ANY salivary tissue remains; ineffective in complete gland destruction (post-radiotherapy complete destruction). Any sugar-free gum or lozenge is suitable; claims of added benefit from xylitol are not established. Sugar-free hard sweets (mints, lozenges): similar reflex stimulation. Avoid acidic salivary stimulants (malic/citric acid sweets, drops or pastilles) in dentate patients — they can increase enamel erosion and caries risk, particularly with frequent use. Use neutral-pH products where possible and involve the dental team if symptoms require frequent use.

Pilocarpine (systemic sialogogue)

Pilocarpine (per current SPC and local formulary): a reasonable option for significant oral sicca where residual gland function remains. BSR suggests starting low and titrating gradually, e.g. 5 mg once daily increasing stepwise to 5 mg three times daily (SPC maximum 30 mg daily in divided doses). Muscarinic M3 receptor agonist — directly stimulates salivary acinar cells. Effective only if residual functional salivary tissue exists (works in Sjogren, medication-induced, mild-moderate radiation-induced; ineffective in complete glandular destruction). Evidence: RCTs show significant improvement in UWSFR and patient-reported symptoms. Onset: 1-2 weeks. Check contraindications against the current SPC rather than a fixed list. Cautions include asthma or chronic obstructive airway disease, narrow-angle glaucoma or acute iritis, significant cardiac disease or bradyarrhythmia, peptic ulcer disease, renal or hepatic impairment, urinary obstruction, sweating and dehydration, and dizziness or visual disturbance affecting driving. Side effects: sweating (most common), flushing, urinary frequency, GI upset — dose-limiting. Cevimeline is not licensed in the UK.

The pilocarpine prescribing decision for xerostomia requires clinical assessment of residual salivary gland function — pilocarpine is a muscarinic receptor agonist that stimulates saliva secretion from acinar cells, but it can only work if there are functional acinar cells remaining. In Sjögren disease, some acinar tissue is often preserved (especially early in the disease), and pilocarpine can improve salivary flow and symptoms. In post-radiotherapy xerostomia, efficacy depends on the degree of acinar destruction — with extensive gland destruction there may be little functional tissue to stimulate. The practical prescribing approach: after checking SPC contraindications, start low (e.g. 5 mg once daily) and titrate gradually, taken with food (reduces GI side effects), review at 4-6 weeks for objective benefit assessment (has the patient noticed any subjective improvement?), and discontinue if no benefit after 6-8 weeks of adequate dosing.

Treat

Dental Protection, Oral Candida & Sjogren Disease Management

Done

Dental protection in xerostomia

Arrange dental assessment for high caries risk. The dentist may prescribe high-fluoride toothpaste or apply fluoride varnish. Brush twice daily, spit out and do not rinse immediately after brushing. If fluoride mouthwash is used, use it at a different time from brushing. The choice of fluoride concentration and frequency is based on dental assessment, caries risk, age, patient ability and local dental guidance — a 5,000 ppm toothpaste is not automatically required for every patient with xerostomia. Regular dental review at an interval set by the dentist according to caries risk. Avoid sugar-containing foods and acidic beverages between meals. Fluoride varnish (applied by the dentist at a frequency set by caries risk). Remineralising agents: CPP-ACP (Recaldent — GC Tooth Mousse) — applied after brushing, particularly at night.

Oral candidiasis management in xerostomia

Candida colonisation and infection is markedly increased in xerostomia — saliva has antifungal properties (IgA, lactoferrin, histatins) that are lost when flow is reduced. Presentation: denture stomatitis (erythema under denture — most common form), pseudomembranous candidiasis (white plaques), erythematous candidiasis (red, smooth, painful mucosa), angular cheilitis. Confirm candidiasis by oral examination before treating. Treatment per NICE CKS, local formulary and SPC: miconazole oral gel first line; nystatin suspension if miconazole is unsuitable, including patients on warfarin (miconazole raises the INR — bleeding risk); systemic (e.g. fluconazole) for extensive or severe disease — do not assume fluconazole is simply more effective; check drug interactions (particularly warfarin and some statins) and renal dose adjustment. Denture-associated candidiasis: treat the dentures as well as the mouth — remove dentures overnight, clean with denture brush and soak in a suitable cleanser. Review treatment if candidiasis recurs.

Sjogren syndrome systemic management

Symptomatic relief: artificial saliva, pilocarpine, ocular lubricants (preservative-free) — see the dry eye disease protocol. Hydroxychloroquine is not a treatment for isolated oral dryness — it may be considered by rheumatology for selected systemic symptoms (arthralgia, cutaneous disease, fatigue); evidence for sicca improvement is limited. Specialist/shared-care responsibility; dose based on actual body weight per current rheumatology guidance, generally not exceeding 5 mg/kg/day. Retinal monitoring (OCT and fundus autofluorescence, with visual fields where indicated) usually begins after 5 years, or after 1 year with high-risk factors (eGFR <60, tamoxifen, dose >5 mg/kg/day) (RCOphth 2020; SPS). Check QT-prolongation interactions; warn about cardiomyopathy; visual symptoms need urgent assessment. Immunosuppression (specialist-led): for severe extraglandular disease — prednisolone + azathioprine or mycophenolate; rituximab for refractory systemic disease. Follow-up is systemic-risk based: no routine annual LDH, β2-microglobulin or SPEP for every patient — laboratory testing is guided by rheumatology and disease manifestations (BSR 2024).

Next steps: see Dry eye disease

High-fluoride toothpaste and fluoride varnish for xerostomia-related dental protection should be dental-led, based on caries risk. The rationale: saliva normally provides a continuous supply of calcium, phosphate, and fluoride that remineralises tooth enamel throughout the day — in xerostomia, this protective mechanism is absent, and caries can develop rapidly (particularly at the cervical margin, under crown margins, and on root surfaces). Fluoride helps compensate for the loss of the mineralising effect of saliva. The patient instruction: apply a pea-sized amount, brush for 2 minutes, spit but do not rinse (leaving the fluoride residue on tooth surfaces maximises uptake). This simple prescribing intervention prevents the cascade of extraction, denture fitting, and denture-related problems that xerostomia can cause.

Lifestyle

Oral Hygiene, Hydration & Environmental Measures

Done

Hydration and oral moistening strategies Encourage regular small sips and adequate hydration unless fluid restriction applies (e.g. heart failure, advanced CKD, liver disease, hyponatraemia). Avoid excessive water intake. Keep a small water bottle bedside for nocturnal dry mouth. Ice chips (crushed ice, ice lollies — sugar-free): dissolve slowly, providing prolonged oral moistening. Caffeine is not necessarily dehydrating at moderate intake — advise patients to identify whether caffeine worsens their symptoms rather than avoiding it universally. Alcohol: salivary gland depressant and drying agent — reduce or abstain. Spicy and acidic foods: may worsen oral mucosal irritation in severe xerostomia — moderate intake.

Dietary modifications for dry mouth Food texture: soft, moist foods are easier to eat with xerostomia — stews, casseroles, soups, pasta with sauce, yoghurt, scrambled eggs. Dry, crumbly, and sticky foods present the greatest difficulty: crackers, bread, peanut butter, dry meat. Moisten food with gravy, sauces, or broth before eating. Chew thoroughly and take sips of water with each mouthful. Avoid: very sweet or acidic foods (caries risk), fizzy drinks, citrus juices (erosion on demineralised xerostomic teeth). Sugar-free options for all confectionery and chewing gum.

Environmental humidification Consider humidification for selected patients with nocturnal dryness (evidence is limited), but clean the device regularly according to the manufacturer's instructions and avoid stagnant water — poorly maintained devices can become contaminated. Nasal saline spray: if mouth breathing is secondary to nasal obstruction, treating nasal congestion may reduce oral dryness.

Oral hygiene routine for xerostomia Brush twice daily with fluoride toothpaste (high-fluoride only if the dentist prescribes it); spit out and do not rinse immediately after brushing. Use a soft-bristle toothbrush (hard bristles traumatise dry mucosa more easily). Interdental cleaning daily. If fluoride mouthwash is used, use it at a different time from brushing. Avoid: alcohol-containing mouthwashes (e.g. Listerine — alcohol is a desiccant and worsens xerostomia). Use alcohol-free alternatives.

Denture care in xerostomia Dentures fit poorly in xerostomia (saliva provides adhesion and suction for denture retention). Denture adhesive (Fixodent, Poligrip): improves retention when salivary film is insufficient. Remove dentures overnight (prevents pressure sores and candida overgrowth on atrophic mucosa); treat dentures as well as the mouth if candidiasis occurs. Clean with denture brush + mild soap, soak in water (not bleach-based cleaners for metal-containing dentures). Annual dental review for denture adjustment (atrophic mucosa under dentures compresses more readily without salivary cushioning).

Medication review at every consultation Review the full medication list at every dry mouth consultation — the Anticholinergic Cognitive Burden (ACB) scale should be applied. Aim to reduce cumulative anticholinergic burden where safe. Consider switching: amitriptyline → nortriptyline (lower ACB, equally effective for neuropathic pain/sleep); oxybutynin → mirabegron (beta-3 agonist for OAB — no anticholinergic effect); chlorphenamine → cetirizine or loratadine (ACB 0 non-sedating antihistamines); first-generation antipsychotics → lower-anticholinergic equivalents (discuss with prescribing psychiatrist). Document all medication changes and reasoning in clinical notes.

Post-radiotherapy xerostomia prevention and management Radiotherapy technique and any cytoprotection are oncology decisions. Post-radiotherapy: pilocarpine only after contraindication and residual-function assessment, a formulary saliva substitute (check ACBS criteria — some products are ACBS-approved for radiotherapy-related xerostomia), dental-led fluoride and dental review according to caries risk. Acupuncture evidence is limited; it is not a routine NHS recommendation.

Psychological impact of chronic xerostomia Chronic dry mouth significantly impairs quality of life: difficulty eating socially (embarrassing coughing/choking on dry food), altered taste (reduced taste intensity and altered taste quality — xerostomia reduces gustatory stimulation), speech difficulty (dry oral mucosa increases vocal fatigue and the urge to clear the throat), sleep disruption (nocturnal dry mouth causes repeated waking), social isolation (difficulty speaking in public settings). Ask about mood at Sjögren reviews (PHQ-9/GAD-7 where helpful) — depression is more common in Sjögren disease. NHS Talking Therapies referral. Sjogren's UK (sjogrens.org.uk): peer support, practical tips, and national awareness.

Lifestyle measures for dry mouth relieve symptoms but have a limited evidence base, so they should be offered pragmatically rather than as fixed targets. Hydration advice must respect fluid restriction (heart failure, advanced CKD, liver disease, hyponatraemia); caffeine avoidance is individual rather than universal; humidifiers may help selected people with nocturnal dryness but must be cleaned regularly; no single saliva substitute is clearly superior, and neutral-pH products are preferable for dentate patients (NHS SPS). Efficacy claims for xylitol, acupuncture and humidifiers are not established and should not be presented as proven.

Safety

Follow-Up, Monitoring & Dental Liaison

Done

Sjogren syndrome GP monitoring

Systemic-risk based; no routine annual LDH, β2-microglobulin or SPEP for every patient — laboratory testing is guided by rheumatology and disease manifestations. GP review covers: symptoms and function; new parotid swelling or lymphadenopathy; weight loss, night sweats and fevers; purpura; neuropathy; renal symptoms; respiratory symptoms; medication toxicity; dental and ophthalmological care. Hydroxychloroquine: retinal monitoring usually from 5 years, or from 1 year with high-risk factors (eGFR <60, tamoxifen, dose >5 mg/kg/day). Refer promptly: new or asymmetric parotid enlargement, lymphadenopathy, B symptoms, purpura, cytopenias, new neuropathy or renal disease.

Dental monitoring for xerostomia

Dental review at an interval set by the dentist according to caries risk. Fluoride use as advised by the dentist. New caries: prompt treatment (xerostomia caries progress rapidly — early intervention is tooth-saving). Denture review annually. Oral candida: screen at each review.

Medication review timeline

ACB score review at every prescription change. If new anticholinergic medication added: pre-emptively discuss dry mouth as an expected side effect and provide saliva substitute and water advice. If dry mouth worsens: reassess full medication list + ACB.

Pilocarpine monitoring

Review at 4-6 weeks: objective benefit (UWSFR if measured, subjective improvement). Dose-limiting side effects (sweating, flushing): reduce the dose. Check contraindications and cautions against the current SPC before prescribing (including airway disease, glaucoma/iritis, cardiac disease, peptic ulcer, renal/hepatic impairment, urinary obstruction, effects on driving).

Urgent ENT referral (local pathway)

Persistent, unexplained or suspicious salivary gland swelling (local head and neck/ENT pathway; urgent if firm mass, facial weakness, fixation or neck nodes) · Unilateral painless hard parotid mass · Parotid mass with facial nerve palsy or cervical lymphadenopathy · Rapidly enlarging or asymmetric gland

Rheumatology / oral medicine

Suspected Sjögren disease (sicca complex ± anti-Ro/La positivity) → specialist assessment and diagnosis

Rheumatology urgent

Bilateral parotid enlargement of unknown cause · Sjögren disease with B symptoms, cytopenias, lymphadenopathy, purpura or new systemic disease

Safety-net (say it, document it)

Same day: “Contact us the same day for a gland swelling that grows quickly, becomes painful, hot or red, or comes with fever or weakness of one side of the face; or for great thirst, passing a lot of urine and weight loss.” 999: “Call 999 if you are vomiting and drowsy or breathing fast.” This week: “Book an appointment if a lump in a gland or the neck does not go away, or for weight loss, night sweats, a rash of small purple spots or new numbness.”

The Sjogren syndrome to lymphoma surveillance responsibility is shared between GP, rheumatology, and haematology — GPs who are reviewing Sjogren patients annually must act on the warning signs of lymphoma: new asymmetric parotid enlargement, persistent lymphadenopathy (particularly cervical), unexplained weight loss, drenching night sweats, palpable purpura, new cytopenias, or a monoclonal gammopathy. Specialists combine disease activity (ESSDAI) with lymphoma risk markers (persistent gland swelling, low C4, cryoglobulins); monitoring frequency and tests are set by systemic involvement and risk features (BSR 2024). The most actionable principle for GPs: any of these warning features in a Sjögren patient = prompt rheumatology/haematology referral; imaging is a specialist decision.